[go: up one dir, main page]

WO1991011525A3 - Vaccins - Google Patents

Vaccins Download PDF

Info

Publication number
WO1991011525A3
WO1991011525A3 PCT/GB1991/000107 GB9100107W WO9111525A3 WO 1991011525 A3 WO1991011525 A3 WO 1991011525A3 GB 9100107 W GB9100107 W GB 9100107W WO 9111525 A3 WO9111525 A3 WO 9111525A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
gene
recombinant virus
region
recombinant
Prior art date
Application number
PCT/GB1991/000107
Other languages
English (en)
Other versions
WO1991011525A2 (fr
Inventor
Norman Spibey
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Priority to CA002074502A priority Critical patent/CA2074502C/fr
Priority to EP91903143A priority patent/EP0512017B1/fr
Priority to DE69126606T priority patent/DE69126606T2/de
Priority to KR1019920701760A priority patent/KR920703831A/ko
Publication of WO1991011525A2 publication Critical patent/WO1991011525A2/fr
Publication of WO1991011525A3 publication Critical patent/WO1991011525A3/fr
Priority to GR970401882T priority patent/GR3024242T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à un adénovirus recombinant agissant comme vecteur pour un gène producteur d'antigènes (tel qu'un gène de glycoprotéine rabique) et qui comprend une souche de CAV-2 modifiée de façon à contenir la séquence des gènes promoteurs à l'intérieur de la région allant du site SmaI proche de l'extrémité de la répétition terminale inversée jusqu'au promoteur pour la région précoce 4 (E4). Pour faciliter la réplication, le virus recombinant est transfecté dans une lignée cellulaire exprimant des protéines Ela. Ce virus recombinant est utilisé pour la production d'un vaccin correspondant.
PCT/GB1991/000107 1990-01-25 1991-01-25 Vaccins WO1991011525A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002074502A CA2074502C (fr) 1990-01-25 1991-01-25 Vaccins
EP91903143A EP0512017B1 (fr) 1990-01-25 1991-01-25 Vaccins
DE69126606T DE69126606T2 (de) 1990-01-25 1991-01-25 Vakzine
KR1019920701760A KR920703831A (ko) 1990-01-25 1991-01-25 백신(vaccines)
GR970401882T GR3024242T3 (en) 1990-01-25 1997-07-25 Vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9001766.6 1990-01-25
GB909001766A GB9001766D0 (en) 1990-01-25 1990-01-25 Vaccines

Publications (2)

Publication Number Publication Date
WO1991011525A2 WO1991011525A2 (fr) 1991-08-08
WO1991011525A3 true WO1991011525A3 (fr) 1991-09-05

Family

ID=10669925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000107 WO1991011525A2 (fr) 1990-01-25 1991-01-25 Vaccins

Country Status (14)

Country Link
EP (1) EP0512017B1 (fr)
JP (1) JP3159446B2 (fr)
KR (1) KR920703831A (fr)
AU (1) AU641211B2 (fr)
CA (1) CA2074502C (fr)
DE (1) DE69126606T2 (fr)
DK (1) DK0512017T3 (fr)
ES (1) ES2103001T3 (fr)
GB (1) GB9001766D0 (fr)
GR (1) GR3024242T3 (fr)
HU (1) HUT65368A (fr)
NZ (1) NZ236887A (fr)
WO (1) WO1991011525A2 (fr)
ZA (1) ZA91534B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT510773E (pt) * 1991-04-25 2004-04-30 Akzo Nobel Nv Vacina subunidade do coronavirus canino
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US6099831A (en) * 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
CA2594375C (fr) 1997-06-23 2015-12-22 University Of Saskatchewan Genome de l'adenovirus bovin de type 3
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
CA2410665C (fr) 2000-05-31 2017-11-07 University Of Saskatchewan Adenovirus bovin modifie avec modification du tropisme
US6916635B2 (en) 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
FR2845395B1 (fr) * 2002-10-08 2008-05-30 Agronomique Inst Nat Rech Vecteurs adenoviraux recombinants et leurs applications
EP1606419A1 (fr) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
WO2005049794A2 (fr) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Procedes de caracterisation du virus de la bursite infectieuse
BRPI0507929A (pt) 2004-02-19 2007-07-17 Univ Alberta polimorfismos de promotor de leptina e seus usos
US7803612B2 (en) 2005-04-25 2010-09-28 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2012030720A1 (fr) 2010-08-31 2012-03-08 Merial Limited Vaccins contre le virus herpétique à base de vecteurs du virus de la maladie de newcastle
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012138789A2 (fr) 2011-04-04 2012-10-11 Netherlands Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2012145509A2 (fr) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Séquences rep de virus adéno-associé, vecteurs, et virus
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2012149038A1 (fr) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
WO2012166493A1 (fr) 2011-06-01 2012-12-06 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (fr) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Antigènes de poil de streptococcus suis
WO2013093629A2 (fr) 2011-12-20 2013-06-27 Netherlands Cancer Institute Vaccins modulaires, procédés et compositions qui y sont liés
WO2013138776A1 (fr) 2012-03-16 2013-09-19 Merial Limited Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
WO2014164697A1 (fr) 2013-03-12 2014-10-09 Merial Limited Compositions vaccinales contre le virus de schmallenberg obtenues par génétique inverse, et leurs méthodes d'utilisation
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
PL3313864T3 (pl) 2015-06-23 2022-01-03 Boehringer Ingelheim Animal Health USA Inc. Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania
MX381745B (es) 2015-08-31 2025-03-13 Boehringer Ingelheim Vetmedica Gmbh Vacunas de pestivirus para temblores congenitos.
CA2996613A1 (fr) 2015-09-16 2017-03-23 Boehringer Ingelheim Vetmedica, Inc. Vaccins contre salmonella choleraesuis-salmonella typhimurium
EP3515480A1 (fr) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH Nouveau vaccin contre la grippe porcine
KR102618843B1 (ko) 2016-09-20 2024-01-02 베링거잉겔하임베트메디카게엠베하 신규한 ehv 삽입 부위 orf70
JP6913747B2 (ja) 2016-09-20 2021-08-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ イヌアデノウイルスベクター
JP7187448B2 (ja) 2016-09-20 2022-12-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 新しいプロモーター
MY191895A (en) 2016-11-03 2022-07-18 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
JP6876127B2 (ja) 2016-11-03 2021-05-26 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ ブタパルボウイルスに対するワクチン
EA201991762A1 (ru) 2017-01-30 2020-01-23 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вакцины против коронавируса свиней
JP7083362B2 (ja) 2017-07-12 2022-06-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド セネカウイルスａ免疫原性組成物およびその方法
JP7038804B2 (ja) 2017-09-23 2022-03-18 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー パラミクソウイルス科の発現系
WO2019092027A1 (fr) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Compositions immunogènes à base de sapelovirus et leurs utilisations
US11033616B2 (en) 2018-02-23 2021-06-15 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
CN111867625B (zh) 2018-03-19 2024-09-17 勃林格殷格翰动物保健有限公司 具有失活ul18和/或ul8的新ehv
WO2019179966A1 (fr) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh Site d'insertion d'ehv ul43
MX2020010018A (es) 2018-03-26 2020-10-14 Boehringer Ingelheim Animal Health Usa Inc Metodo para producir una composicion inmunogenica.
CN112867505B (zh) 2018-09-20 2024-10-01 勃林格殷格翰动物保健有限公司 经修饰的pedv刺突蛋白
WO2020058341A1 (fr) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Vaccin à vecteur par voie intranasale contre la diarrhée épidémique porcine
EP4100420A1 (fr) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides utiles pour la détection d'anticorps anti-rhabdovirus
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
EP4225776A1 (fr) 2020-10-05 2023-08-16 Boehringer Ingelheim Vetmedica GmbH Protéine de fusion utile pour la vaccination contre les rotavirus
AR128992A1 (es) 2022-04-05 2024-07-03 Boehringer Ingelheim Vetmedica Gmbh Composición inmunógena útil para la vacunación contra el rotavirus
WO2024243578A1 (fr) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Antigènes synthétiques de cancers en tant que cibles pour le traitement de cancers
WO2025171383A2 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés et procédés et utilisations associés
WO2025171388A1 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés avec des domaines modifiés et procédés et utilisations associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (fr) * 1984-11-01 1986-05-14 American Home Products Corporation Vaccins oraux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (fr) * 1984-11-01 1986-05-14 American Home Products Corporation Vaccins oraux

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gene, volume 55, 1987, Elsevier Science B.V., M. Shinagawa et al.: "Phylogenetic relationships between adenoviruses as inferred from nucleotide sequences of inverted terminal repeats", page 85 *
J. Gen. Virol., Volume 70, 1989, SGM, N. Spibey et al.: "Molecular cloning and restriction endonuclease mapping oftwo strains of canine adenovirus type 2", pages 165-172 *
Journal of Virology, volume 54, no. 3, June 1985, American Society for Microbiology, I. Saito et al.: "Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome", pages 711-719 *
Technological Advances in Vaccine Development, 1988, Alan R. Liss, Inc., F.L. Graham et al.: "Cloning and expression of glycoprotein genes in human adenovirus vectors 1", pages 243-253 *
Trends in Biotechnology, volume 8, no. 4, April 1990, Elsevier Science Publishers Ltd, (Cambridge, GB), F.L. Graham: "Adenoviruses as expression vectors and recombinant vaccines", pages 85-87 *
Virus Research, volume 14, 1989, Elsevier Science Publishers B.V., N. Spibey et al.: "Identification and nucleotide sequence of the early region 1 from canine adenovirus types 1 and 2" pages 241-256 *

Also Published As

Publication number Publication date
DK0512017T3 (da) 1998-01-19
CA2074502C (fr) 2001-07-17
DE69126606T2 (de) 1998-01-08
DE69126606D1 (de) 1997-07-24
AU641211B2 (en) 1993-09-16
ZA91534B (en) 1991-11-27
WO1991011525A2 (fr) 1991-08-08
HU9202436D0 (en) 1992-12-28
ES2103001T3 (es) 1997-08-16
KR920703831A (ko) 1992-12-18
NZ236887A (en) 1992-04-28
JPH05505306A (ja) 1993-08-12
EP0512017A1 (fr) 1992-11-11
GR3024242T3 (en) 1997-10-31
EP0512017B1 (fr) 1997-06-18
HUT65368A (en) 1994-05-02
AU7075691A (en) 1991-08-21
GB9001766D0 (en) 1990-03-28
CA2074502A1 (fr) 1991-07-26
JP3159446B2 (ja) 2001-04-23

Similar Documents

Publication Publication Date Title
WO1991011525A3 (fr) Vaccins
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
KR970701782A (ko) 생체내에서 유전자의 통합성 발현(Coordinate in vivo gene expression)
EP0596979A4 (en) Recombinant plant viral nucleic acids.
EE200300331A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EP0766569A4 (fr) Capsides de virus adeno-associe utilises comme vecteurs pour le transfert moleculaire
SG55158A1 (en) Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
IE821428L (en) Foot and mouth disease vaccine
AU7335296A (en) Recombinant sendai virus
EP1605052A3 (fr) Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine
ES2061671T3 (es) Sistema de expresion transitoria para producir proteina recombinante.
ES2000278A6 (es) Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica.
GB9023111D0 (en) Expression system
EP0261940A3 (fr) Vaccins pseudorabiques et vecteurs d'ADN pour recombiner avec les poxvirus
AU5572786A (en) Expression of immunologically reactive aids viral protein
DK564789D0 (da) Fremgangsmaade til ekspression af et eukaryot gen
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
CA2461579A1 (fr) Region e1 de l'adenovirus porcin
AU605155B2 (en) A structural phosphoprotein (PP 15) of human cytomegalovirus, and the preparation and use thereof
EP0112012A3 (fr) Molécules recombinantes d'ADN
EP0460217A4 (en) Cdna of orsv gene
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ
TH33841A (th) รีคอมบิแนนท์เอวิพอคซ์ไวรัส การเพาะเลี้ยงเซลล์ที่ติดเชื้อไวรัสนี้ และวัคซีนสำหรับสัตว์ปีกที่อนุพัทธ์จากไวรัสนี้

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991903143

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2074502

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991903143

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991903143

Country of ref document: EP